Back to Search
Start Over
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.
- Source :
-
Frontiers in immunology [Front Immunol] 2022 Jun 10; Vol. 13, pp. 873195. Date of Electronic Publication: 2022 Jun 10 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- COVID-19 has proven to be particularly serious and life-threatening for patients presenting with pre-existing pathologies. Patients affected by rheumatic musculoskeletal disease (RMD) are likely to have impaired immune responses against SARS-CoV-2 infection due to their compromised immune system and the prolonged use of disease-modifying anti-rheumatic drugs (DMARDs), which include conventional synthetic (cs) DMARDs or biologic and targeted synthetic (b/ts) DMARDs. To provide an integrated analysis of the immune response following SARS-CoV-2 infection in RMD patients treated with different classes of DMARDs we carried out an immunological analysis of the antibody responses toward SARS-CoV-2 nucleocapsid and RBD proteins and an extensive immunophenotypic analysis of the major immune cell populations. We showed that RMD individuals under most DMARD treatments mount a sustained antibody response to the virus, with neutralizing activity. In addition, they displayed a sizable percentage of effector T and B lymphocytes. Among b-DMARDs, we found that anti-TNFα treatments are more favorable drugs to elicit humoral and cellular immune responses as compared to CTLA4-Ig and anti-IL6R inhibitors. This study provides a whole picture of the humoral and cellular immune responses in RMD patients by reassuring the use of DMARD treatments during COVID-19. The study points to TNF-α inhibitors as those DMARDs permitting elicitation of functional antibodies to SARS-CoV-2 and adaptive effector populations available to counteract possible re-infections.<br />Competing Interests: Author EM is employed by Dia.Pro (Diagnostic Bioprobes srl, Milan, Italy). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Favalli, Favalli, Gobbini, Zagato, Bombaci, Maioli, Pesce, Donnici, Gruarin, Biggioggero, Curti, Manganaro, Marchisio, Bevilacqua, Martinovic, Fabbris, Sarnicola, Crosti, Marongiu, Granucci, Notarbartolo, Bandera, Gori, De Francesco, Abrignani, Caporali and Grifantini.)
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 35757699
- Full Text :
- https://doi.org/10.3389/fimmu.2022.873195